Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 7/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.46 |
| ▸ | VSIR | Q9H7M9 | 9/20 | 0.44 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10247410 | 0.94 | S1PR1 (0.50) | S1PR1S1PR3VSIRENPP3ENPP1 | |
| SCHEMBL10247088 | 0.93 | S1PR1 (0.44) | S1PR1S1PR3VSIRENPP3ENPP1 | |
| SCHEMBL2805596 | 0.86 | S1PR1 (0.63) | S1PR1S1PR3VSIR | |
| SCHEMBL2805557 | 0.80 | S1PR1 (0.59) | S1PR1S1PR3VSIR | |
| SCHEMBL10247062 | 0.80 | S1PR1 (0.44) | S1PR1S1PR3ENPP3ENPP1CD274 | |
| SCHEMBL2806790 | 0.80 | S1PR1 (0.68) | S1PR1S1PR3VSIR | |
| SCHEMBL2806714 | 0.76 | S1PR1 (0.62) | S1PR1S1PR3VSIRCD274PDCD1 | |
| SCHEMBL2809504 | 0.75 | S1PR1 (0.61) | S1PR1S1PR3VSIR | |
| SCHEMBL2805534 | 0.74 | S1PR1 (0.64) | S1PR1S1PR3 | |
| SCHEMBL19339805 | 0.74 | S1PR1 (0.67) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | S1PR1 448/4885S1PR3 310/4885VSIR 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.